Full Breakdown
FDA's New Vaccine Approval Standards Amid Concerns Over COVID-19 Shots for Children
11/30/2025, 8:40:31 AM
Overview of the FDA's Vaccine Review Changes
The Food and Drug Administration (FDA) is implementing stricter standards for vaccine approvals, particularly concerning COVID-19 vaccines for children. This decision follows an internal review led by Dr. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, which concluded that at least 10 children died "after and because of receiving" the COVID vaccine. This finding has raised significant concerns regarding the safety of these vaccines and the agency's regulatory practices.
Key Findings and Internal Review
Dr. Prasad's memo, which spans 3,000 words, indicated that of 96 child deaths reported to the Vaccine Adverse Event Reporting System (VAERS) between 2021 and 2024, at least 10 were linked to COVID vaccination. He suggested that the actual number could be higher, criticizing the FDA for allegedly ignoring safety concerns. However, the memo did not provide specific details about the children's ages, medical histories, or the vaccine manufacturers involved.
Criticism from Public Health Experts
The claims made in Prasad's memo have faced substantial pushback from public health experts. Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia, criticized the lack of evidence supporting the assertion that the vaccines caused these deaths. He emphasized the need for transparency and peer review, stating, "All this will do is scare people unnecessarily."
Dr. Michael Osterholm, an epidemiologist at the University of Minnesota, also challenged the memo's conclusions, arguing that it misrepresents the severity of COVID-19 in children, which resulted in 1,597 deaths from 2020 to 2022. He called for an independent review of the alleged vaccine-associated deaths before accepting Prasad's claims.
Proposed Changes to Vaccine Approval Processes
In light of these findings, the FDA plans to revise its vaccine approval processes. This includes requiring pneumonia vaccine manufacturers to demonstrate that their products reduce disease rather than merely generating antibodies. Additionally, the agency will reassess how annual flu vaccines are evaluated, moving away from what Prasad termed "low quality evidence."
Official Responses and Ongoing Monitoring
Moderna, a manufacturer of COVID vaccines approved for children, stated that it is unaware of any deaths linked to its vaccine in the past year and emphasized the safety of its product based on multiple peer-reviewed studies. The FDA and the Centers for Disease Control and Prevention (CDC) continue to monitor vaccine safety through VAERS, although the system is known for its limitations in establishing cause-and-effect relationships.
Implications for Public Health
The FDA's new stance on vaccine approvals could lead to fewer vaccines being available, potentially impacting public health efforts to protect children from infectious diseases. As the CDC prepares for a significant meeting to review childhood vaccination policies, there are concerns that these changes may disrupt established vaccination schedules, leading to lower immunization rates and the resurgence of preventable diseases.
Verbatim Quotes
- “This is sort of science by press release,” — Dr. Paul Offit, Director, Vaccine Education Center at the Children's Hospital of Philadelphia
- “This memo conveys a very troubling mixture of misrepresentation and lies,” — Dr. Peter Marks, Former Vaccine Chief, FDA
- “For the first time, the U.S. FDA will acknowledge that COVID-19 vaccines have killed American children.” — Dr. Vinay Prasad, Director, FDA’s Center for Biologics Evaluation and Research
Conflicting Reports & Gaps
There is a notable discrepancy regarding the evidence supporting the claim that COVID vaccines caused the deaths of 10 children. Critics argue that the data from VAERS is often misinterpreted and lacks rigorous validation. Furthermore, the FDA's findings have not been published in a peer-reviewed journal, raising questions about their credibility and the methodology used in the internal review.
